ALNY - Alnylam Pharmaceuticals Inc
(NaN%)
Sell
Weak Growth●Earnings/Profit is Negative
30%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 138.78%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -111.82%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 4.38
Debt Ratio is 0.78
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.12
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Alnylam Pharmaceuticals Inc (ALNY) - www.alnylam.com
Alnylam Pharmaceuticals Inc. is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam's partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its 'Alnylam P5x25' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.Exchange - NASDAQ/NGS (GLOBAL SELECT MARKET)
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - John Maraganore
Employees - 1,453
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.